قالب وردپرس درنا توس
Home / Business / AstraZeneca’s (AstraZeneca) CEO said its COVID-19 vaccine will achieve 95% efficacy, and its stock price rose 4%

AstraZeneca’s (AstraZeneca) CEO said its COVID-19 vaccine will achieve 95% efficacy, and its stock price rose 4%



Pascal Soriot, CEO of AstraZeneca.JPG
In 2014, Pascal Soriot, CEO of AstraZeneca, held it in London.

  • CEO Pascal Soriot told the Sunday Times last weekend that the COVID-19 vaccine developed by AstraZeneca can effectively prevent the virus with a 95% effect.
  • Soriot also said that he believes the vaccine can prevent the new COVID-19 strain, which is more infectious than the original strain and is spreading across the UK.
  • AstraZeneca submitted vaccine data to the British health regulator last week. Emergency use authorization may be coming soon and is expected to be promoted to British citizens early next week.
  • In Monday̵
    7;s trading, AstraZeneca shares rose 4%.
  • Watch AstraZeneca trade here.

According to the “Daily Telegraph” report, the COVID-19 vaccine developed by AstraZeneca may receive emergency use authorization from the British regulator on Monday or Tuesday this week and is expected to be launched to British citizens in the first week of 2021. This vaccine.

AstraZeneca submitted its COVID-19 vaccine data to the UK regulator on December 23. CEO Pascal Soriot believes that the data will show that its vaccine is as effective as 95% of Pfizer and BioNtech in preventing COVID-19 infection. .

Soriot said in an interview with The Sunday Times: “We think we have figured out the magic weapon to win and how to obtain effective effects. After two doses, everyone else can use it.”

Soriot told the newspaper that the vaccine data will be released at some point.

On Monday, AstraZeneca shares rose 4% to $50.28.

read more: “The 20-something that may soar will end in a terrible end”: A stock president who oversees more than $7 billion in stocks shared his investment story and main predictions for 2021 and beyond

Soriot added that he believes that AstraZeneca’s COVID-19 vaccine will protect the new strain of the virus, which is believed to be more infectious than the original strain and is circulating in the UK.

In an interview with The Sunday Times, Soriot said: “We think this vaccine should still be effective against this new strain,” adding that “we are not sure, so we will test it.”

Since the two-dose vaccine does not require cryopreservation like the mRNA vaccines developed by Moderna and Pfizer/BioNtech, the highly effective COVID-19 vaccine from AstraZeneca can speed up the promotion of the vaccine to all parts of the world.

The AstraZeneca vaccine requires a refrigeration temperature of 36°F to 46°F and can be stored for at least six months.

The United States has signed a 300 million dose vaccine contract with AstraZeneca, surpassing its US$200 million order for Moderna and Pfizer/BioNtech vaccines.

read more: Deutsche Bank says you need to own these 10 telecommunications stocks, because advances in vaccines will stimulate a weak industry recovery in 2022


Source link